Figure 4
Impact of the IPRS on survival of patients in the external validation cohort. OS of all 293 AML patients (A) and of the 131 CN-AML patients (B) according to assignment to the low-, intermediate-, or high-risk groups (2-sided log-rank test).
Impact of the IPRS on survival of patients in the external validation cohort. OS of all 293 AML patients (A) and of the 131 CN-AML patients (B) according to assignment to the low-, intermediate-, or high-risk groups (2-sided log-rank test).
